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Short summary 
Steroid pulse therapy with methylprednisolone succinate ester (mPSL) is the most 
common treatment for neuromyelitis optica (NMO); no cases of anaphylaxis have been 
reported to date. Here, we report two cases of anaphylactic shock induced by mPSL pulse 
therapy in patients with NMO and concurrent systemic lupus erythematosus. Both 
patients had received several courses of mPSL pulse therapy without any problems 
previously. Repeated mPSL pulse therapy and comorbid humoral autoimmune disease 
might increase the risk of anaphylaxis. Corticosteroids without succinate esters should be 
considered as an alternative therapy to prevent anaphylaxis.  
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Neuromyelitis optica (NMO) is characterized by recurrent optic neuritis and transverse 
myelitis. Steroid pulse therapy with methylprednisolone succinate ester (mPSL) is the 
most common treatment for the relapse phase of NMO as well as multiple sclerosis (MS). 
Here we report two cases of anaphylactic shock induced by mPSL pulse therapy in 
patients with anti-aquaporin-4 antibody-positive NMO who had previously undergone 
several courses of mPSL pulse therapy for relapses without any problems. Our report 
offers suggestions about the pathogenesis and risk of anaphylaxis with corticosteroids 
with succinate esters and highlights the efficacy of therapeutic alternatives involving 
corticosteroids without succinate esters. 
 
Case reports 
The first case involved a 27-year-old woman with a 1-year history of NMO and a 
13-year history of systemic lupus erythematosus (SLE). She had been treated with 15 
mg/day of PSL and 1 mg/kg/day of azathioprine. To date, she has had five attacks of NMO 
and/or central nervous system (CNS) lupus. For each episode, she had received mPSL 
pulse therapy without any serious adverse effects. Subsequently, she developed a new 
relapse in the cervical spinal cord, for which mPSL pulse therapy was also selected. Seven 
minutes after mPSL administration began, she suddenly developed anaphylactic shock 
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with a whole-body urticarial reaction, dyspnea, hypoxia (peripheral oxygen saturation 
88%), and hypotension (systolic blood pressure of approximately 70 mmHg). She 
immediately recovered from anaphylactic shock upon intravenous epinephrine 
administration. 
The second case involved a 29-year-old woman with a 3-year history of 
NMO and a 22-year history of SLE. She had been treated with 15 mg/day of PSL and 1 
mg/kg/day of azathioprine. To date, she has had more than 10 relapses, which have been 
treated with mPSL pulse therapy without any serious adverse effects. She received mPSL 
pulse therapy again for a new lesion in the right optic nerve. Ten minutes after mPSL 
administration began, she had anaphylactic reactions manifested as urticaria in the limbs 
and hypotension (systolic blood pressure of approximately 90 mmHg) followed by 
sudden delirium. She immediately recovered from anaphylactic shock upon cessation of 
mPSL administration. 
Intradermal allergy tests for six injectable corticosteroids consisting of 
mPSL, prednisolone succinate ester (PSL), hydrocortisone succinate ester (HDC-
succinate), hydrocortisone phosphate ester (HDC-phosphate), dexamethasone (DEX), 
and betamethasone (BMS) revealed that succinate-containing corticosteroids (mPSL, 
PSL, and HDC-succinate) induced strong allergic reaction in both patients, but not 
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steroids with phosphate esters (HDC-phosphate, DEX, and BMS). Importantly, both 
patients recovered from their NMO relapse with an alternative steroid pulse regiment 
consisting of BMS or DEX without any allergic reactions. 
 
Discussion 
This is the first report documenting anaphylaxis in patients with NMO 
caused by mPSL pulse therapy. Six cases of anaphylaxis in patients with MS caused by 
mPSL pulse therapy have been reported to date.1-6 Interestingly, five of six patients 
received multiple courses of mPSL pulse therapy before anaphylaxis (Table 1). 
Sensitization with repeated mPSL treatments has been suggested as a causative 
mechanism of anaphylaxis.7 Our patients have also received repeated courses of mPSL 
pulse therapy, which may have led to acquired mPSL antigenicity. Previous reports have 
proposed immunological dysregulation as another risk factor for developing mPSL-
induced anaphylaxis. Asthma, renal transplantation, rheumatic disease, hypersensitivity 
to nonsteroidal anti-inflammatory drugs are examples of immunological dysregulation.7 
Both patients had SLE in addition to NMO. Such co-existence of humoral autoimmune 
diseases might have increased susceptibility to developing hypersensitization as previous 
reports have suggested.8 Our observations suggest that the combination of repeated mPSL 
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exposure and concurrent SLE may increase the risk of anaphylaxis from corticosteroids 
with succinate esters.  
The reasons why corticosteroids with succinate esters cause allergic 
reactions more frequently than those without succinate esters are fully elucidated.9,10 A 
previous study proposed that the immunogenic role of succinate esters could be attributed 
to their greater solubility in water and higher affinity for serum proteins. These properties 
might change the presentation of the steroid molecule from a hapten to a complete 
antigen.9 Accordingly, corticosteroids without succinate esters seldom cause anaphylactic 
reactions, even in patients with hypersensitivity against mPSL although cross-reactivity 
with DEX or other steroids might underlie a rare cause of hypersensitivity.9,10 In fact, 
mPSL succinate ester was the drug causing anaphylaxis in all reported MS cases, and 
corticosteroids without succinate esters (i.e., DEX or BMS) were used as alternative drugs 
(Table 1). In the present cases, intradermal allergy tests strikingly identified succinate-
containing corticosteroids as the cause and demonstrated that corticosteroids with 
phosphate esters were not antigenic. Of clinical importance, our observations suggest that 
alternative steroid pulse therapies involving corticosteroids with phosphate esters such as 
DEX and BMS could be safe and effective. 
In conclusion, our case report suggests that all NMO patients treated with 
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repeated mPSL pulse therapy, especially patients with comorbid humoral autoimmune 
diseases known to be frequently associated with NMO, have a higher risk of anaphylaxis 
caused by mPSL. In such cases, special caution should be exercised when using mPSL. 
For example, injectable epinephrine should be prepared in advance. Furthermore, 
alternative steroid pulse therapies consisting of corticosteroids without succinate esters 
should be selected in patients with a history of anaphylaxis.   
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